Medikaloka Hermina (Indonesia) Performance
| HEAL Stock | IDR 1,220 65.00 5.06% |
The company secures a Beta (Market Risk) of -0.0898, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Medikaloka Hermina are expected to decrease at a much lower rate. During the bear market, Medikaloka Hermina is likely to outperform the market. At this point, Medikaloka Hermina has a negative expected return of -0.23%. Please make sure to verify Medikaloka Hermina's coefficient of variation, information ratio, total risk alpha, as well as the relationship between the standard deviation and jensen alpha , to decide if Medikaloka Hermina performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Medikaloka Hermina PT has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's forward-looking signals remain quite persistent which may send shares a bit higher in April 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
| Begin Period Cash Flow | 864.6 B | |
| Total Cashflows From Investing Activities | -1.2 T |
Medikaloka |
Medikaloka Hermina Relative Risk vs. Return Landscape
If you would invest 141,500 in Medikaloka Hermina PT on December 19, 2024 and sell it today you would lose (19,500) from holding Medikaloka Hermina PT or give up 13.78% of portfolio value over 90 days. Medikaloka Hermina PT is generating negative expected returns and assumes 2.6511% volatility on return distribution over the 90 days horizon. Simply put, 23% of stocks are less volatile than Medikaloka, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Medikaloka Hermina Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medikaloka Hermina's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Medikaloka Hermina PT, and traders can use it to determine the average amount a Medikaloka Hermina's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0849
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HEAL |
Estimated Market Risk
| 2.65 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.23 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Medikaloka Hermina is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medikaloka Hermina by adding Medikaloka Hermina to a well-diversified portfolio.
Medikaloka Hermina Fundamentals Growth
Medikaloka Stock prices reflect investors' perceptions of the future prospects and financial health of Medikaloka Hermina, and Medikaloka Hermina fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medikaloka Stock performance.
| Return On Equity | 0.14 | |||
| Return On Asset | 0.0704 | |||
| Profit Margin | 0.1 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 23.44 T | |||
| Shares Outstanding | 14.48 B | |||
| Price To Earning | 7.42 X | |||
| Price To Book | 6.72 X | |||
| Price To Sales | 4.66 X | |||
| Revenue | 5.82 T | |||
| EBITDA | 1.9 T | |||
| Cash And Equivalents | 590.19 B | |||
| Cash Per Share | 40.20 X | |||
| Total Debt | 1.47 T | |||
| Debt To Equity | 0.41 % | |||
| Book Value Per Share | 230.87 X | |||
| Cash Flow From Operations | 1.86 T | |||
| Earnings Per Share | 32.62 X | |||
| Total Asset | 7.59 T | |||
About Medikaloka Hermina Performance
By examining Medikaloka Hermina's fundamental ratios, stakeholders can obtain critical insights into Medikaloka Hermina's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Medikaloka Hermina is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
PT Medikaloka Hermina Tbk operates a network of general hospitals in Indonesia. The company was founded in 1999 and is based in Jakarta, Indonesia. Medikaloka Hermina operates under Medical Care Facilities classification in Indonesia and is traded on Jakarta Stock Exchange. It employs 10547 people.Things to note about Medikaloka Hermina performance evaluation
Checking the ongoing alerts about Medikaloka Hermina for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Medikaloka Hermina help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medikaloka Hermina generated a negative expected return over the last 90 days | |
| About 51.0% of the company shares are held by company insiders |
- Analyzing Medikaloka Hermina's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medikaloka Hermina's stock is overvalued or undervalued compared to its peers.
- Examining Medikaloka Hermina's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medikaloka Hermina's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medikaloka Hermina's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medikaloka Hermina's stock. These opinions can provide insight into Medikaloka Hermina's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Medikaloka Stock
Medikaloka Hermina financial ratios help investors to determine whether Medikaloka Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medikaloka with respect to the benefits of owning Medikaloka Hermina security.